Senti Biosciences is trading 5.03% higher at $0.35, apparently on continued speculative interest and trading momentum; no clear September 24 catalyst was identified.

  • Shares gained 7.10% on September 23.
  • Recent coverage highlights financing and merger-related filings, including an amended securities agreement and a planned $2.0 million note tranche.
  • Broader markets and biotech are lower, so sector weakness does not explain the advance.